CDC73 and parathyroid gland carcinoma: Thus, it is recommended that deletion analysis of the CDC73 gene should be performed in HPT-JT, FIHP, parathyroid carcinoma, or severe early-onset PHPT patients who do not have CDC73 point mutations (15, –, 17).